News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Intrexon (XON) Names Christopher Basta Vice President Of Investor Relations

5/19/2014 7:48:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GERMANTOWN, Md., May 19, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Christopher Basta as Vice President of Investor Relations, effective immediately. Mr. Basta will report directly to Chairman and Chief Executive Officer Randal J. Kirk.

Intrexon Corporation logo

Mr. Basta brings more than 18 years of financial experience to Intrexon. Most recently, he was a consultant for DSP Group directing its investor relations initiatives. Prior to his consulting work, Mr. Basta spent the majority of his Wall Street career at Royal Bank of Canada, where over nine years he helped establish its Middle Markets division and subsequently transitioned to assist in the growth of its Institutional Equity Sales division. He left RBC in 2011 to join GM Advisory Group as Managing Director and Portfolio Manager for its internal hedge fund where he implemented various investment strategies across both public securities and private equity. Mr. Basta also previously served as Vice President at both Lehman Brothers and First Union. He earned a B.S. in Communications from the State University of New York, Albany.

Mr. Kirk commented, "Chris has an integrated knowledge of capital markets and strategic communications that make him an ideal addition to the Intrexon team. He can clearly communicate the Intrexon investment thesis and supportive facts, and he possesses a deep understanding of investors of many types. We are excited to have Chris join our management team and believe he will make an excellent addition as we continue to grow our business and drive investor interest to create value for the Company and its shareholders."

Mr. Basta added, "The suite of proprietary technologies that Intrexon has constructed over the past 16 years positions it at the forefront of the synthetic biology industry, which has the potential to redefine many of the world's health, food, energy, consumer and environmental challenges. The Company's Exclusive Channel Collaboration model is unique in its ability to capture the significant opportunity at hand in an extremely capital efficient manner, and its equity ownership and royalty structure provide multiple paths to deliver shareholder returns. I am pleased to join Intrexon's strong team at this exciting time and look forward to working with current and future shareholders."

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer Sectors to create biologically-based products that improve the quality of life and the health of the planet. Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Intrexon's current expectations and projections about future events and generally relate to Intrexon's plans, objectives and expectations for the development of Intrexon's business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. These risks and uncertainties include, but are not limited to, (i) Intrexon's current and future ECCs and joint ventures; (ii) developments concerning Intrexon's collaborators; (iii) Intrexon's ability to successfully enter new markets or develop additional products, whether with its collaborators or independently; (iv) competition from existing technologies and products or new technologies and products that may emerge; (v) actual or anticipated variations in Intrexon's operating results; (vi) actual or anticipated fluctuations in Intrexon's competitors' or its collaborators' operating results or changes in their respective growth rates; (vii) Intrexon's cash position; (viii) market conditions in Intrexon's industry; (ix) Intrexon's ability, and the ability of its collaborators, to protect Intrexon's intellectual property and other proprietary rights and technologies; (x) Intrexon's ability, and the ability of its collaborators, to adapt to changes in laws or regulations and policies; (xi) the ability of Intrexon's collaborators to secure any necessary regulatory approvals to commercialize any products developed under the ECCs; (xii) the rate and degree of market acceptance of any products developed by a collaborator under an ECC; (xiii) Intrexon's ability to retain and recruit key personnel; (xiv) Intrexon's expectations related to the use of proceeds from its initial public offering; (xv) Intrexon's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and (xvi) Intrexon's expectations relating to AquaBounty. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Intrexon's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Intrexon's Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intrexon's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intrexon undertakes no duty to update this information unless required by law.

For more information regarding Intrexon Corporation, contact:

Corporate Contact:

Investor Contact:

Marie Rossi

The Ruth Group

Corporate Communications

Intrexon Corporation

Tel: +1 (301) 556-9850

David Burke

Tel: +1 (646) 536-7009

Logo -

SOURCE Intrexon Corporation

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus